Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy for recurrent miscarriage.

J R Scott1

  • 1Department of Obstetrics and Gynaecology, University of Utah Medical Centre, 50 North Medical Drive, Salt Lake City, Utah 84132, USA. jscott@hsc.utah.edu

The Cochrane Database of Systematic Reviews
|May 5, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of interferon-gamma release assay results and their association with COVID-19 infection outcomes.

IJTLD open·2024
Same author

Correction to: Characterization of host response, resorption, and strength properties, and performance in the presence of bacteria for fully absorbable biomaterials for soft tissue repair.

Hernia : the journal of hernias and abdominal wall surgery·2024
Same author

Optogenetic stimulation of striatal patches modifies habit formation and inhibits dopamine release.

Scientific reports·2021
Same author

What are the immunological and clinical implications of microchimerism?

BJOG : an international journal of obstetrics and gynaecology·2018
Same author

Safety of eliminating postpartum magnesium sulphate: intriguing but not yet proven.

BJOG : an international journal of obstetrics and gynaecology·2018
Same author

Characterization of host response, resorption, and strength properties, and performance in the presence of bacteria for fully absorbable biomaterials for soft tissue repair.

Hernia : the journal of hernias and abdominal wall surgery·2017
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
Same journal

Non-pharmacological interventions for anxiety and depression in Parkinson's disease.

The Cochrane database of systematic reviews·2026
Same journal

Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis.

The Cochrane database of systematic reviews·2026
See all related articles

Immunologic treatments like leukocyte immunization and IVIG do not improve live birth rates for women with recurrent miscarriages. These therapies, including paternal cell immunization, showed no significant benefit over placebo in preventing further pregnancy loss.

Area of Science:

  • Reproductive Immunology
  • Obstetrics and Gynecology

Background:

  • Recurrent early pregnancy loss may stem from immunologic factors in some women.
  • Identifying effective treatments for unexplained recurrent miscarriages is crucial for reproductive health.

Purpose of the Study:

  • To evaluate the efficacy of leukocyte immunization and other immunologic treatments, such as intravenous immune globulin (IVIG), for improving live birth rates.
  • To assess the impact of these immunotherapies in women with a history of unexplained recurrent miscarriages.

Main Methods:

  • Systematic review of randomized controlled trials identified through the Cochrane Pregnancy and Childbirth Group trials register, MEDLINE, and the American Society for Reproductive Immunology.
  • Inclusion criteria focused on women with three or more prior miscarriages, limited live births, and exclusion of non-immunologic causes.

Related Experiment Videos

  • Data from 18 high-quality trials were analyzed, comparing various immunotherapy interventions against control groups.

    • Main Results:

    • Paternal cell immunization demonstrated an odds ratio of 1.05 (95% CI 0.75–1.47).
    • Third-party donor cell immunization yielded an odds ratio of 1.39 (95% CI 0.68–2.82).
    • Intravenous immune globulin (IVIG) showed an odds ratio of 1.14 (95% CI 0.66–1.95), with no significant differences observed for trophoblast membrane infusion either.

    Conclusions:

    • Current evidence suggests that paternal cell immunization, third-party donor leukocytes, trophoblast membranes, and IVIG do not offer a significant benefit over placebo.
    • These immunologic interventions are not proven effective in preventing recurrent miscarriages.
    • Further research may be needed to explore alternative or refined immunotherapeutic approaches for recurrent pregnancy loss.